IONIS PHARMACEUTICALS INC
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $IONS in the last 30 days.
See all $IONS insider activity →The FDA approved 13 drugs in September 2026, including Zanvastro (IONS) for Alexander disease, Omcazio (6620.TWO) for various cancers, Etcamah (AZN) for breast cancer, Pixclara (TLX) for glioma diagnosis, and ISEMBLYD (SRRK) for SMA. Key pricing and clinical data were reported.
The EU drug regulator's expert panel endorsed six new medicines and five label expansions in October 2026, benefiting Eli Lilly, Pfizer, and Johnson & Johnson. Lilly's weight loss pill Foundayo and Pfizer's breast cancer therapy Tukysa received positive opinions. Johnson & Johnson's cancer therapy Talvey was recommended for an indication extension. Other companies like Ionis, Regeneron, and Revolution Medicines also received positive opinions for their respective drugs.
CHMP recommended EU approval for Ionis Pharmaceuticals' TRYNGOLZA (olezarsen) for sHTG, ahead of schedule. A final decision is expected in Q4 2026. This follows prior U.S. approval and Phase 3 data, indicating progress toward EU commercialization.
Over the past 7 days, AlphAI's AI scored 14 news stories mentioning IONS (IONIS PHARMACEUTICALS INC). Coverage has skewed bullish: 14 bullish, 0 neutral, and 0 bearish.
Recent IONS coverage spans regulation and financial news.
Approval adds a novel, high‑priced therapy to Ionis pipeline, likely boosting share price.
Expanded label may increase US and EU uptake.
EU approval could unlock a sizable market and boost revenue expectations.
Initiating coverage with a high target could spark demand for IONS shares.
Approval creates a new revenue stream for Ionis and may boost its stock on the news.
AlphAI scores every news story that mentions IONS with an AI model for sentiment and relevance, and aggregates insider trades from IONIS PHARMACEUTICALS INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
The FDA approved 13 drugs in September 2026, including Zanvastro (IONS) for Alexander disease, Omcazio (6620.TWO) for various cancers, Etcamah (AZN) for breast cancer, Pixclara (TLX) for glioma diagnosis, and ISEMBLYD (SRRK) for SMA. Key pricing and clinical data were reported.
3 min readThe EU drug regulator's expert panel endorsed six new medicines and five label expansions in October 2026, benefiting Eli Lilly, Pfizer, and Johnson & Johnson. Lilly's weight loss pill Foundayo and Pfizer's breast cancer therapy Tukysa received positive opinions. Johnson & Johnson's cancer therapy Talvey was recommended for an indication extension. Other companies like Ionis, Regeneron, and Revolution Medicines also received positive opinions for their respective drugs.
2 min readCHMP recommended EU approval for Ionis Pharmaceuticals' TRYNGOLZA (olezarsen) for sHTG, ahead of schedule. A final decision is expected in Q4 2026. This follows prior U.S. approval and Phase 3 data, indicating progress toward EU commercialization.
1 min readAnalysts at Truist Financial maintained a Buy rating on Boston Scientific (BSX) with a $51 target, while J.P. Morgan set a $56 target. Ionis Pharmaceuticals (IONS) received a Buy rating from Truist with an $88 target, and RBC Capital set an $85 target. Both stocks have Strong Buy consensus ratings.
2 min readIonis Pharmaceuticals' Zanvastro, the first approved treatment for Alexander disease, targets the underlying genetic cause. Clinical trials showed improved motor function. The drug, developed with University of Wisconsin-Madison researchers, will be available in the U.S. and internationally via Recordati. Alexander disease is rare, affecting fewer than 1 in a million people.
2 min readAnalysts from UBS, Bank of America, and H.C. Wainwright provided ratings and price targets for Johnson & Johnson (JNJ), United Therapeutics (UTHR), and Ionis Pharmaceuticals (IONS). JNJ has a Strong Buy consensus with a $289.71 target, UTHR has a Moderate Buy consensus with a $643.00 target, and IONS has a Strong Buy consensus with an $84.00 target.
2 min readRBC Capital analysts maintained Buy ratings on CSL (CMXHF), Ionis Pharmaceuticals (IONS), and Cormedix (CRMD). CSL's price target is A$215.00, IONS's is $85.00, and CRMD's is $14.00. Analysts' consensus ratings are Moderate Buy for CSL and Strong Buy for IONS and CRMD.
2 min readIonis Pharmaceuticals (IONS) shares rose 4.39% as investors reassess its prospects following recent FDA approvals and Phase 3 trial successes. The company's growing product slate and RNA-based medicine platform are noted, but cash burn and debt remain concerns. YTD performance is -45.27%.
2 min readFour biotech companies are hiring: Scholar Rock (SRRK) has 30 open roles and recently received FDA approval for Isembyld (SMA treatment). Insmed (INSM) has over 100 positions open and is advancing gene therapies for DMD and ALS. Ionis Pharmaceuticals (IONS) has 35 roles available and recently gained FDA approvals for Zanvastro (Alexander disease) and Tryngolza (hypertriglyceridemia). Dyne Therapeutics (DYN) has around 60 open positions and is advancing treatments for DMD and FSHD.
3 min readIonis Pharmaceuticals and Roche reported positive Phase 3 interim data for sefaxersen in treating primary IgA nephropathy, meeting proteinuria endpoints. The company is still loss-making, with a net loss of $565.2 million on $874.1 million revenue. Analysts project $2.2 billion revenue and $261.6 million earnings by 2029, assuming 36.3% annual growth. Success depends on execution, pricing, and partner coordination.
3 min read
